| Antigen: |
CD19 |
| Relevance: |
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin’s lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase |
| Clone: |
PDR134 |
| Subclass: |
IgM |
| Applications: |
Immunohistochemistry (frozen sections), FACS |
| Immunogen: |
Pokeweek-stimulated Daudi and Raji cells |
| Reactivity: |
Human |
| Species raised in: |
Mouse |
| Fusion partner: |
NS-1 |
| Recommended growth conditions: |
RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| References: |
Tedder TF, Wagner N, Engel P (1995) B-cell antigens: section report. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 1, Oxford University Press, Oxford, New York and Tokyo, p 491.
Sato S, Tedder TF (1997) CD19 Workshop Panel report. In Kishimoto T, et al (eds) Leucocyte Typing VI, Garland Publishing Inc., New York and London, p 133-135 |
| Notes: |
Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Click here to view Notes and Disclaimer information |
